COUMARIN--PROHIBITED
General Information
Mainterm | COUMARIN--PROHIBITED |
Doc Type | BAN |
CAS Reg.No.(or other ID) | 91-64-5 |
Regnum |
189.130 |
From www.fda.gov
Computed Descriptors
Download SDF2D Structure | |
CID | 323 |
IUPAC Name | chromen-2-one |
InChI | InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H |
InChI Key | ZYGHJZDHTFUPRJ-UHFFFAOYSA-N |
Canonical SMILES | C1=CC=C2C(=C1)C=CC(=O)O2 |
Molecular Formula | C9H6O2 |
Wikipedia | coumarin |
From Pubchem
Computed Properties
Property Name | Property Value |
---|---|
Molecular Weight | 146.145 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Complexity | 196.0 |
CACTVS Substructure Key Fingerprint | A A A D c Y B w M A A A A A A A A A A A A A A A A A A A A A A A A A A w Q A A A A A A A A A C B A A A A G g A A A A A A D A S A m A A w D o A A B A C I A i D S C A A C C A A g I A A I i A A G C M g M J i K E M R q C O i C k w B E I q Y e A w C A O A A A A A A A I A A A A A A A A A B A A A A A A A A A A A A = = |
Topological Polar Surface Area | 26.3 |
Monoisotopic Mass | 146.037 |
Exact Mass | 146.037 |
Compound Is Canonicalized | True |
Formal Charge | 0 |
Heavy Atom Count | 11 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Isotope Atom Count | 0 |
Covalently-Bonded Unit Count | 1 |
From Pubchem
Food Additives Biosynthesis/Degradation
ADMET Predicted Profile --- Classification
Model | Result | Probability |
---|---|---|
Absorption | ||
Blood-Brain Barrier | BBB+ | 0.9565 |
Human Intestinal Absorption | HIA+ | 0.9912 |
Caco-2 Permeability | Caco2+ | 0.9155 |
P-glycoprotein Substrate | Non-substrate | 0.6697 |
P-glycoprotein Inhibitor | Non-inhibitor | 0.8540 |
Non-inhibitor | 0.8663 | |
Renal Organic Cation Transporter | Non-inhibitor | 0.8301 |
Distribution | ||
Subcellular localization | Mitochondria | 0.4995 |
Metabolism | ||
CYP450 2C9 Substrate | Non-substrate | 0.7966 |
CYP450 2D6 Substrate | Non-substrate | 0.9117 |
CYP450 3A4 Substrate | Non-substrate | 0.7139 |
CYP450 1A2 Inhibitor | Inhibitor | 0.9117 |
CYP450 2C9 Inhibitor | Non-inhibitor | 0.6943 |
CYP450 2D6 Inhibitor | Non-inhibitor | 0.9105 |
CYP450 2C19 Inhibitor | Non-inhibitor | 0.5000 |
CYP450 3A4 Inhibitor | Non-inhibitor | 0.8310 |
CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.8115 |
Excretion | ||
Toxicity | ||
Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.8702 |
Non-inhibitor | 0.9474 | |
AMES Toxicity | Non AMES toxic | 0.8870 |
Carcinogens | Non-carcinogens | 0.9412 |
Fish Toxicity | High FHMT | 0.6109 |
Tetrahymena Pyriformis Toxicity | High TPT | 0.9544 |
Honey Bee Toxicity | High HBT | 0.8062 |
Biodegradation | Ready biodegradable | 0.5884 |
Acute Oral Toxicity | II | 0.7019 |
Carcinogenicity (Three-class) | Warning | 0.5324 |
From admetSAR
ADMET Predicted Profile --- Regression
Model | Value | Unit |
---|---|---|
Absorption | ||
Aqueous solubility | -2.7525 | LogS |
Caco-2 Permeability | 1.7653 | LogPapp, cm/s |
Distribution | ||
Metabolism | ||
Excretion | ||
Toxicity | ||
Rat Acute Toxicity | 2.4622 | LD50, mol/kg |
Fish Toxicity | 1.2095 | pLC50, mg/L |
Tetrahymena Pyriformis Toxicity | 0.6735 | pIGC50, ug/L |
From admetSAR
Toxicity Profile
Route of Exposure | None |
---|---|
Mechanism of Toxicity | None |
Metabolism | None |
Toxicity Values | None |
Lethal Dose | None |
Carcinogenicity (IARC Classification) | 3, not classifiable as to its carcinogenicity to humans. |
Minimum Risk Level | None |
Health Effects | None |
Treatment | None |
Reference |
|
From T3DB
Taxonomic Classification
Kingdom | Organic compounds |
---|---|
Superclass | Phenylpropanoids and polyketides |
Class | Coumarins and derivatives |
Subclass | Not available |
Intermediate Tree Nodes | Not available |
Direct Parent | Coumarins and derivatives |
Alternative Parents | |
Molecular Framework | Aromatic heteropolycyclic compounds |
Substituents | Coumarin - 1-benzopyran - Benzopyran - Pyranone - Benzenoid - Pyran - Heteroaromatic compound - Lactone - Oxacycle - Organoheterocyclic compound - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Aromatic heteropolycyclic compound |
Description | This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one). |
From ClassyFire
Targets
- General Function:
- Steroid hydroxylase activity
- Specific Function:
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
- Gene Name:
- CYP2A6
- Uniprot ID:
- P11509
- Molecular Weight:
- 56501.005 Da
- General Function:
- Zinc ion binding
- Specific Function:
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
- Gene Name:
- ESR1
- Uniprot ID:
- P03372
- Molecular Weight:
- 66215.45 Da
References
- Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB: Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. [23611293 ]
From T3DB